Differential protein expression patterns obtained by mass spectrometry can aid in the diagnosis of Hodgkin's disease

Journal of Experimental Therapeutics and Oncology

Volumn 6, Issue 2, 2007, Pages 137-145

  Carvalho, Paulo Costa ^a,b   Carvalho, Maria Da Gloria Costa ^b   Degrave, Wim ^a   Lilla, Sergio ^c   De Nucci, Gilberto ^c   Fonseca, Raul ^d   Spector, Nelson ^b   Musacchio, Juliane ^b   Domont, Gilberto Barbosa ^b  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

Author keywords

Feature selection; Hodgkin's disease; Lymphoma; Pattern recognition; Proteomics

Indexed keywords

ARTICLE; CANCER CELL; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; EARLY DIAGNOSIS; HODGKIN DISEASE; HUMAN; MASS SPECTROMETRY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEOMICS;

BLOOD PROTEINS; HODGKIN DISEASE; HUMANS; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 33947407619     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Conrads TP, Hood BL, Issaq HJ, Veenstra TD: Proteomic patterns as a diagnostic tool for early-stage cancer: a review of its progress to a clinically relevant tool. Mol Diagn 8:77-85, 2004.
2. Troyer DA, Mubiru J, Leach RJ, Naylor SL: Promise and challenge: Markers of prostate cancer detection, diagnosis and prognosis. Dis Markers 20:117-128, 2004.
3. Beebe-Dimmer JL, Lange LA, Cain JE, Lewis RC, Ray AM, Sarma AV et al.: Polymorphisms in the prostate-specific antigen gene promoter do not predict serum prostate-specific antigen levels in African-American men. Prostate Cancer Prostatic Dis 9:50-55, 2005.
4. Ruiz-Martin I, Rodriguez-Sanchez CA, Ocana-Fernandez A, Del Valle-Zapico J, Soto dP-O, Cruz-Hernandez JJ: Metastatic prostate cancer with a normal prostate-specific antigen level. Clin Transl Oncol 7:412-413, 2005.
5. McGreevy K, Rodgers K, Lipsitz S, Bissada N, Hoel D: Impact of race and baseline PSA on longitudinal PSA. Int J Cancer 7:1773-1776, 2005.
6. Curran V, Solberg S, Mathews M, Church J, Buehler S, Wells J et al.: Prostate cancer screening attitudes and continuing education needs of primary care physicians. J Cancer Educ 20:162-166, 2005.
7. Wasinger VC, Cordwell SJ, Cerpa-Poljak A, Van JX, Gooley AA, Wilkins MR et al.: Progress with gene-product mapping of the Mollicutes: Mycoplasma genitalium. Electrophoresis 16:1090-1094, 1995.
8. Steel LF, Mattu TS, Mehta A, Hebestreit H, Dwek R, Evans AA et al.: A proteomic approach for the discovery of early detection markers of hepatocellular carcinoma. Dis Markers 17:179-189, 2001.
9. Ardekani AM, Liotta LA, Petricoin EF, III: Clinical potential of proteomics in the diagnosis of ovarian cancer. Expert Rev Mol Diagn 2:312-320, 2002.
10. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW: Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 48:1296-1304, 2002.
11. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH et al.: Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 62:3609-3614, 2002.
12. Qu Y, Adam BL, Yasui Y, Ward MD, Cazares LH, Schellhammer PF et al.: Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 48:1835-1843, 2002.
13. Wagner M, Naik DN, Pothen A, Kasukurti S, Devineni RR, Adam BL et al.: Computational protein biomarker prediction: a case study for prostate cancer. BMC Bioinformatics 5:26, 2004.
14. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM et al.: Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359:572-577, 2002.
15. Lilien RH, Farid H, Donald BR: Probabilistic disease classification of expression-dependent proteomic data from mass spectrometry of human serum. J Comput Biol 10:925-946, 2003.
16. Mehta AI, Ross S, Lowenthal MS, Fusaro V, Fishman DA, Petricoin EF, III et al.: Biomarker amplification by serum carrier protein binding. Dis Markers 19:1-10, 2003.
17. Vapnik VN: The nature of statistical learning theory. Jordan M, Lauritzen F, Lawless J, Nair V., eds. Springer-Verlag: New York, Inc. 1995.
18. Shan S C., Kusiak A: Data mining and genetic algorithm based gene/SNP selection. Artifitial Intelligence in Medicine 2004. 31:183-196.
19. Liu CL, Sako H, Fujisawa H: Effects of classifier structures and training regimes on integrated segmentation and recognition of handwritten numeral strings. IEEE Trans Pattern Anal Mach Intell 26:1395-1407, 2004.
20. Haimowitz IJ, Kohane IS: Managing temporal worlds for medical trend diagnosis. Artif Intell Med 8:299-321, 1996.
21. Brusco MJ: An enhanced branch-and-bound algorithm for a partitioning problem. Br J Math Stat Psychol 56:83-92, 2003.
22. Lin G, Xu D, Chen ZZ, Jiang T, Wen J, Xu Y: An efficient branch-and-bound algorithm for the assignment of protein backbone NMR peaks. Proc IEEE Comput Soc Bioinform Conf 1:165-174, 2002.
23. Pupko T, Pe'er I, Hasegawa M, Graur D, Friedman N: A branch-and-bound algorithm for the inference of ancestral amino-acid sequences when the replacement rate varies among sites: Application to the evolution of five gene families. Bioinformatics 18:1116-1123, 2002.
24. Yeh JY, Fu JC, Wu CC, Lin HM, Chai JW: Myocardial border detection by branch-and-bound dynamic programming in magnetic resonance images. Comput Methods Programs Biomed 79:19-29, 2005.
25. Wasan KM, Wong JC, Corr T, Pritchard S: Role of plasma lipids and lipoproteins in predicting amphotericin B-induced nephrotoxicity in pediatric oncology patients. Cancer Chemother Pharmacol 57:120-124, 2005.
26. Kolakowska A, Malina W: Fisher sequential classifiers. IEEE Trans Syst Man Cybern B Cybern 35:988-998, 2005.
27. Gulsrud TO, Husoy JH: Optimal filter-based detection of microcalcifications. IEEE Trans Biomed Eng 48:1272-1281, 2001.
28. Guyon I, Weston J, Barnhill S, Vapnik V. Gene Selection for Cancer Classification using Support Vector Machines. Mach Learn 46:389-422, 2002.
29. Thomas RK, Re D, Wolf J, Diehl V: Part I: Hodgkin's lymphoma - molecular biology of Hodgkin and Reed-Sternberg cells. Lancet Oncol 5:11-18, 2004
30. Diehl V, Thomas RK, Re D: Part II: Hodgkin's lymphoma-diagnosis and treatment. Lancet Oncol 5:19-26, 2004
31. Carvalho PC, Fischer J, Silva M, Musacchio J, Spector N, Degrave W et al.: Detection of potential serum molecular markers for Hodgkin's disease. J Bras Patol Med Lab 41:99-103, 2005
32. Joachims T: Making large-Scale SVM Learning Practical. Advances in Kernel Methods - Support Vector Learning. MIT-Press. 1999.
33. Guyon I, Weston J, Barnhill S, Vapnik V. Gene Selection for Cancer Classification using Support Vector Machines. Mach Learn 46:389-422, 2002.
34. Ruiz-Martin I, Rodriguez-Sanchez CA, Ocana-Fernandez A, Del Valle-Zapico J, Soto dP-O, Cruz-Hernandez JJ: Metastatic prostate cancer with a normal prostate-specific antigen level. Clin Transl Oncol 7:412-413, 2005
35. Brawer MK: Prostate-specific antigen: current status. CA Cancer J Clin 49:264-281, 1999.
36. Yasui Y, Pepe M, Thompson ML, Adam BL, Wright GL, Jr., Qu Y et al.: A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection. Biostatistics 4:449-463, 2003.
37. Baggerly KA, Morris JS, Coombes KR: Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics, 20:777-785, 2004.
38. Diamandis EP, van der Merwe DE: Plasma protein profiling by mass spectrometry for cancer diagnosis: opportunities and limitations. Clin Cancer Res 11:963-965, 2005.
39. Diamandis EP: Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 3:367-378, 2004.
40. Diamandis EP: Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 96:353-356, 2004.
41. Diamandis EP: Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem 49:1272-1275, 2003.
42. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM et al.:. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359:572-577, 2002.
43. Yang SY, Xiao XY, Zhang WG, Zhang LJ, Zhang W, Zhou B et al.: Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC Cancer 5:83, 2005.
44. Wang S, Diamond DL, Mass GM, Sokoloff R, Vessella RL: Identification of prostate specific membrane antigen (PSMA) as the target of monoclonal antibody 107-1A4 by proteinchip; array, surface-enhanced laser desorption/ionization (SELDI) technology. Int J Cancer 92:871-876, 2001.
45. Simpkins F, Czechowicz JA, Liotta L, Kohn EC: SELDI-TOF mass spectrometry for cancer biomarker discovery and serum proteomic diagnostics. Pharmacogenomics 6:647-653, 2005.
46. Sauter ER, Shan S, Hewett JE, Speckman P, Du Bois GC: Proteomic analysis of nipple aspirate fluid using SELDI-TOF-MS. Int J Cancer 114:791-796, 2005.
47. Marshall FF: Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. J Urol 173:1919-1920, 2005.
48. Lin Z, Jenson SD, Lim MS, Elenitoba-Johnson KS: Application of SELDI-TOF mass spectrometry for the identification of differentially expressed proteins in transformed follicular lymphoma. Mod Pathol 17:670-678, 2004
49. Becker S, Cazares LH, Watson P, Lynch H, Semmes OJ, Drake RR et al.: Surfaced-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer. Ann Surg Oncol 11:907-914, 2004
50. Baggerly KA, Morris JS, Coombes KR: Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 20:777-785, 2004
51. Diamandis EP, van der Merwe DE: Plasma protein profiling by mass spectrometry for cancer diagnosis: opportunities and limitations. Clin Cancer Res 11:963-965, 2005.
52. Zolotarjova N, Martosella J, Nicol G, Bailey J, Boyes BE, Barrett WC: Differences among techniques for high-abundant protein depletion. Proteomics 5:3304-3313, 2005
53. Echan LA, Tang HY, Li-Khan N, Lee K, Speicher DW: Depletion of multiple high-abundance proteins improves protein profiling capacities of human serum and plasma. Proteomics 5:3292-3303, 2005.
54. Petricoin E, III, Liotta LA: Counterpoint: The vision for a new diagnostic paradigm. Clin Chem 49:1276-1278, 2003.
55. Diamandis EP: Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem 49:1272-1275, 2003
56. Cover TM, Van Campenhout JM. On the possible orderings in the measurement selection problem. IEEE Transactions on Systems, Man, and Cybernetics 9:657-661, 1977.